Strike Pharma

Individual-based cancer treatment

  • CEO: Mårten Winge
  • First investment year: 2021
  • Fund: Eastern Mid Sweden
  • Business sector: Life Science
Strike Pharma

Strike Pharma has developed a new individual-based cancer treatment, based on the genetic profile of each patient tumor, which attacks the tumor cells and leaves other normal cells in the body alone. This way you get more effective treatment while reducing the risk of side effects.